A股異動 | 卓郎智能(600545.SH)漲停 與新疆中泰簽訂100萬錠成套紡紗設備銷售合同
格隆匯2月1日丨卓郎智能(600545.SH)漲停,現報3.19元,封單近11萬手,暫成交1621萬元,最新總市值60億元。卓郎智能上週五(29日)晚間公佈,公司與新疆中泰簽訂貨物買賣合同,本次合同涉及成套紡紗設備約100萬錠,按照當前市場價格,預計整個合同銷售金額約為25億元(具體設備採購的各分合同由雙方或者雙方旗下公司另行簽署)。合作項目內容及時間計劃:2021年完成約50萬錠紡紗項目;2022年完成約50萬錠紡紗項目。若後續按照合同的約定產生銷售,有利於提高公司的銷售收入,對於公司利潤將產生積極影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.